CHROMADEX CORPORATION REPORTS 2019 FINANCIAL RESULTS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
ChromaDex (CDXC) Reports In-Line Q4 EPS, Revenues Beat
March 10, 2020 4:02 PM EDTChromaDex (NASDAQ: CDXC) reported Q4 EPS of ($0.11), in-line with the analyst estimate of ($0.11). Revenue for the quarter came in at $13.1 million versus the consensus estimate of $12.91 million.
Fourth Quarter 2019 Highlights vs. Fourth Quarter 2018
Strong growth in net sales to $13.1 million, higher gross margins, and significantly improved marketing efficiency year-over-year.Tru Niagen® net sales of $10.2 million, a 57% increase year-over-year.Net loss per share of ($0.15) as reported, or... More